{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:43:30Z","timestamp":1794933810641,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2018-12366350"],"award-info":[{"award-number":["GR-2018-12366350"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant epigenetic disorder with highly variable muscle involvement and disease progression. Ongoing clinical trials, aimed at counteracting muscle degeneration and disease progression in FSHD patients, increase the need for reliable biomarkers. Muscle magnetic resonance imaging (MRI) studies showed that the appearance of STIR-positive (STIR+) lesions in FSHD muscles represents an initial stage of muscle damage, preceding irreversible adipose changes. Our study aimed to investigate fibrosis, a parameter of muscle degeneration undetectable by MRI, in relation to disease activity and progression of FSHD muscles. We histologically evaluated collagen in FSHD1 patients\u2019 (STIR+ n\u2009=\u200927, STIR\u2212 n\u2009=\u200928) and healthy volunteers\u2019 (n\u2009=\u200912) muscles by picrosirius red staining. All patients (n\u2009=\u200955) performed muscle MRI before biopsy, 45 patients also after 1\u00a0year and 36 patients also after 2\u00a0years. Fat content (T1 signal) and oedema\/inflammation (STIR signal) were evaluated at baseline and at 1- and 2-year MRI follow-up. STIR+ muscles showed significantly higher collagen compared to both STIR\u2212 (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) and healthy muscles (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). STIR\u2212 muscles showed a higher collagen content compared to healthy muscles (<jats:italic>p<\/jats:italic>\u2009=\u20090.0194). FSHD muscles with a worsening in fatty infiltration during 1- (<jats:italic>P<\/jats:italic>\u2009=\u20090.007) and 2-year (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) MRI follow-up showed a collagen content of 3.6- and 3.7-fold higher compared to FSHD muscles with no sign of progression. Moreover, the fibrosis was significantly higher in STIR+ muscles who showed a worsening in fatty infiltration in a timeframe of 2\u00a0years compared to both STIR\u2212 (<jats:italic>P<\/jats:italic>\u2009=\u20090.0006) and STIR+ muscles with no sign of progression (<jats:italic>P<\/jats:italic>\u2009=\u20090.02). Fibrosis is a sign of muscle degeneration undetectable at MRI never deeply investigated in FSHD patients. Our data show that 23\/27 of STIR+ and 12\/28 STIR\u2212 muscles have a higher amount of collagen deposition compared to healthy muscles. Fibrosis is higher in FSHD muscles with a worsening in fatty infiltration thus suggesting that its evaluation with innovative non-invasive techniques could be a candidate prognostic biomarker for FSHD, to be used to stratify patients and to evaluate the efficacy of therapeutic treatments.<\/jats:p>","DOI":"10.1186\/s40478-023-01660-4","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T16:01:44Z","timestamp":1697558504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Muscle fibrosis as a prognostic biomarker in facioscapulohumeral muscular dystrophy: a retrospective cohort study"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-035X","authenticated-orcid":false,"given":"Elvira","family":"Ragozzino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bortolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Papait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Parolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Monforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Tasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"issue":"1","key":"1660_CR1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13023-021-01760-1","volume":"16","author":"T Shatzl","year":"2021","unstructured":"Shatzl T, Kaiser L, Deigner HP (2021) Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update. Orphanet J Rare Dis 16(1):129","journal-title":"Orphanet J Rare Dis"},{"key":"1660_CR2","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1189044","volume":"329","author":"RJLF Lemmers","year":"2010","unstructured":"Lemmers RJLF, van der Vliet PJ, Klooster R, Sacconi S, Cama\u00f1o P, Dauwerse JG et al (2010) A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 329:1650\u20131653","journal-title":"Science"},{"key":"1660_CR3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/mus.23949","volume":"49","author":"JM Statland","year":"2014","unstructured":"Statland JM, Tawil R (2014) Risk of functional impairment in facioscapulohumeral muscular dystrophy. Muscle Nerve 49:520\u2013527","journal-title":"Muscle Nerve"},{"key":"1660_CR4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/B978-0-444-64076-5.00035-1","volume":"148","author":"R Tawil","year":"2018","unstructured":"Tawil R (2018) Facioscapulohumeral muscular dystrophy. Handb Clin Neurol 148:541\u2013548","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"1660_CR5","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/mus.26064","volume":"57","author":"DG Leung","year":"2018","unstructured":"Leung DG (2018) Magnetic resonance imaging in facioscapulohumeral muscular dystrophy. Muscle Nerve 57(6):872","journal-title":"Muscle Nerve"},{"issue":"9","key":"1660_CR6","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.nmd.2021.07.013","volume":"31","author":"NC Voermans","year":"2021","unstructured":"Voermans NC, Vriens-Munoz Bravo M, Padberg GW, Lafor\u00eat P, FSHD European Trial Network workshop study group, van Alfen N, Attarian S et al (2021) 1st FSHD European Trial Network workshop: working towards trial readiness across Europe. Neuromuscul Disord 31(9):907\u2013918","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"1660_CR7","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.nmd.2020.08.360","volume":"30","author":"J Warman-Chardon","year":"2020","unstructured":"Warman-Chardon J, Diaz-Manera J, Tasca G, Straub V (2020) \u201c247th ENMC International Workshop: muscle magnetic resonance imaging\u2014implementing muscle MRI as a diagnostic tool for rare genetic myopathy cohorts\u201d. Hoofddorp, The Netherlands, September 2019. Neuromuscul Disord 30(11):938\u2013947","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"1660_CR8","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00415-019-09242-y","volume":"266","author":"JR Dahlqvist","year":"2019","unstructured":"Dahlqvist JR, Andersen G, Khawajazada T, Vissing C, Thomsen C, Vissing J (2019) Relationship between muscle inflammation and fat replacement assessed by MRI in facioscapulohumeral muscular dystrophy. J Neurol 266(5):1127\u20131135","journal-title":"J Neurol"},{"issue":"6","key":"1660_CR9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/jcsm.12473","volume":"10","author":"M Monforte","year":"2019","unstructured":"Monforte M, Laschena F, Ottaviani P, Bagnato MR, Pichiecchio A, Tasca G et al (2019) Tracking muscle wasting and disease activity in facioscapulohumeral muscular dystrophy by qualitative longitudinal imaging. J Cachexia Sarcopenia Muscle 10(6):1258\u20131265","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"1660_CR10","doi-asserted-by":"crossref","first-page":"e38779","DOI":"10.1371\/journal.pone.0038779","volume":"7","author":"G Tasca","year":"2012","unstructured":"Tasca G, Pescatori M, Monforte M, Mirabella M, Iannaccone E, Frusciante R et al (2012) Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles. PLoS ONE 7(6):e38779","journal-title":"PLoS ONE"},{"issue":"2","key":"1660_CR11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.nmd.2015.10.005","volume":"26","author":"R Tawil","year":"2016","unstructured":"Tawil R, Padberg GW, Shaw DW, van der Maarel SM, Tapscott SJ (2016) Clinical trial preparedness in facioscapulohumeral muscular dystrophy: clinical, tissue, and imaging outcome measures. Neuromuscul Disord 26(2):181\u2013186","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"1660_CR12","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/hmg\/ddy364","volume":"28","author":"LH Wang","year":"2019","unstructured":"Wang LH, Friedman SD, Shaw D, Snider L, Wong CJ, Budech CB et al (2019) MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD. Hum Mol Genet 28(3):476\u2013486","journal-title":"Hum Mol Genet"},{"issue":"6","key":"1660_CR13","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/hmg\/ddaa031","volume":"29","author":"CJ Wong","year":"2020","unstructured":"Wong CJ, Wang LH, Friedman SD, Shaw D, Campbell AE, Budech CB et al (2020) Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies. Hum Mol Genet 29(6):1030\u20131043","journal-title":"Hum Mol Genet"},{"issue":"Pt 21","key":"1660_CR14","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1242\/jcs.086629","volume":"124","author":"A Uezumi","year":"2011","unstructured":"Uezumi A, Ito T, Morikawa D, Shimizu N, Yoneda T, Segawa M, Yamaguchi M, Ogawa R, Matev MM, Miyagoe-Suzuki Y, Takeda S, Tsujikawa K, Tsuchida K, Yamamoto H, Fukada S (2011) Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle. J Cell Sci 124(Pt 21):3654\u20133664","journal-title":"J Cell Sci"},{"key":"1660_CR15","doi-asserted-by":"crossref","first-page":"e1830","DOI":"10.1038\/cddis.2015.198","volume":"6","author":"J Farup","year":"2015","unstructured":"Farup J, Madaro L, Puri PL, Mikkelsen UR (2015) Interactions between muscle stem cells, mesenchymal-derived cells and immune cells in muscle homeostasis, regeneration and disease. Cell Death Dis 6:e1830\u2013e1913","journal-title":"Cell Death Dis"},{"issue":"12","key":"1660_CR16","doi-asserted-by":"crossref","first-page":"210110","DOI":"10.1098\/rsob.210110","volume":"11","author":"T Molina","year":"2021","unstructured":"Molina T, Fabre P, Dumont NA (2021) Fibro-adipogenic progenitors in skeletal muscle homeostasis, regeneration and diseases. Open Biol 11(12):210110","journal-title":"Open Biol"},{"key":"1660_CR17","doi-asserted-by":"crossref","first-page":"673404","DOI":"10.3389\/fphys.2021.673404","volume":"12","author":"M Theret","year":"2021","unstructured":"Theret M, Rossi FMV, Contreras O (2021) Evolving roles of muscle-resident fibro-adipogenic progenitors in health, regeneration, neuromuscular disorders, and aging. Front Physiol 12:673404","journal-title":"Front Physiol"},{"key":"1660_CR18","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1002\/mus.880181312","volume":"2","author":"K Arahata","year":"1995","unstructured":"Arahata K, Ishihara T, Fukunaga H, Orimo S, Lee JH, Goto K et al (1995) Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Muscle Nerve Suppl 2:S56-66","journal-title":"Muscle Nerve Suppl"},{"issue":"2","key":"1660_CR19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10875-010-9474-6","volume":"31","author":"G Frisullo","year":"2011","unstructured":"Frisullo G, Frusciante R, Nociti R, Tasca G, Renna R, Iorio R et al (2011) CD8+ T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol 31(2):155\u2013166","journal-title":"J Clin Immunol"},{"issue":"4","key":"1660_CR20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/mus.24621","volume":"52","author":"JM Statland","year":"2015","unstructured":"Statland JM, Shah B, Henderson D, Van Der Maarel S, Tapscott SJ, Tawil R (2015) Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies. Muscle Nerve 52(4):521\u2013526","journal-title":"Muscle Nerve"},{"issue":"9","key":"1660_CR21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41419-022-05233-6","volume":"13","author":"L Di Pietro","year":"2022","unstructured":"Di Pietro L, Giacalone F, Ragozzino E, Saccone V, Tiberio F, De Bardi M et al (2022) Non-myogenic mesenchymal cells contribute to muscle degeneration in facioscapulohumeral muscular dystrophy type 1 patients. Cell Death Dis 13(9):793","journal-title":"Cell Death Dis"},{"issue":"5","key":"1660_CR22","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1172\/JCI133303","volume":"130","author":"D Bosnakovski","year":"2020","unstructured":"Bosnakovski D, Shams AS, Yuan C, da Silva MT, Ener ET, Baumann CW, Lindsay AJ et al (2020) Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice. J Clin Invest 130(5):2465\u20132477","journal-title":"J Clin Invest"},{"issue":"3","key":"1660_CR23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3233\/JND-150077","volume":"2","author":"JM Statland","year":"2015","unstructured":"Statland JM, Odrzywolski KJ, Shah B, Henderson D, Fricke AF, van der Maarel SM, Tapscott SJ, Tawil R (2015) Immunohistochemical characterization of facioscapulohumeral muscular dystrophy muscle biopsies. J Neuromuscul Dis 2(3):291\u2013299","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"1660_CR24","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ana.24640","volume":"79","author":"G Tasca","year":"2016","unstructured":"Tasca G, Monforte M, Ottaviani P, Pelliccioni M, Frusciante R, Laschena F et al (2016) Magnetic Resonance Imaging in a large cohort of facioscapulohumeral muscular dystrophy patients: pattern refinement and implications for clinical trials. Ann Neurol 79(5):854\u2013864","journal-title":"Ann Neurol"},{"issue":"6","key":"1660_CR25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/1531-8249(199906)45:6<751::AID-ANA9>3.0.CO;2-M","volume":"45","author":"E Ricci","year":"1999","unstructured":"Ricci E, Galluzzi G, Deidda G, Cacurri S, Colantoni L, Merico B et al (1999) Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol 45(6):751\u2013757","journal-title":"Ann Neurol"},{"key":"1660_CR26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12603-011-0006-8","volume":"15","author":"H Patel","year":"2011","unstructured":"Patel H, Syddall HE, Martin HJ, Cooper C, Stewart C, Sayer AA (2011) The feasibility and acceptability of muscle biopsy in epidemiological studies: findings from the Hertfordshire Sarcopenia Study (HSS). J Nutr Health Aging 15:10\u201315","journal-title":"J Nutr Health Aging"},{"issue":"10","key":"1660_CR27","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1212\/01.wnl.0000324927.28817.9b","volume":"71","author":"D Fischer","year":"2008","unstructured":"Fischer D, Kley RA, Strach K, Meyer C, Sommer T, Eger K et al (2008) Distinct muscle imaging patterns in myofibrillar myopathies. Neurology 71(10):758\u2013765","journal-title":"Neurology"},{"issue":"3","key":"1660_CR28","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00441-018-2955-2","volume":"375","author":"MAA Mahdy","year":"2019","unstructured":"Mahdy MAA (2019) Skeletal muscle fibrosis: an overview. Cell Tissue Res 375(3):575\u2013588","journal-title":"Cell Tissue Res"},{"issue":"5755","key":"1660_CR29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/284470a0","volume":"284","author":"VC Duance","year":"1980","unstructured":"Duance VC, Stephens HR, Dunn M, Bailey AJ, Dubowitz V (1980) A role for collagen in the pathogenesis of muscular dystrophy? Nature 284(5755):470\u2013472","journal-title":"Nature"},{"issue":"3","key":"1660_CR30","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0022-510X(68)90058-0","volume":"7","author":"CD Bell","year":"1968","unstructured":"Bell CD, Conen PE (1968) Histopathological changes in Duchenne muscular dystrophy. J Neurol Sci 7(3):529\u2013544","journal-title":"J Neurol Sci"},{"issue":"7","key":"1660_CR31","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/NEN.0b013e3181aa31c2","volume":"68","author":"I Desguerre","year":"2009","unstructured":"Desguerre I, Mayer M, Leturcq F, Barbet JP, Gherardi RK, Christov C (2009) Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. J Neuropathol Exp Neurol 68(7):762\u2013773","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"1660_CR32","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41467-017-00730-1","volume":"8","author":"D Bosnakovski","year":"2017","unstructured":"Bosnakovski D, Chan SSK, Recht OO, Hartweck LM, Gustafson CJ, Athman LL et al (2017) Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model. Nat Commun 8(1):550","journal-title":"Nat Commun"},{"issue":"2","key":"1660_CR33","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2008","unstructured":"Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214(2):199\u2013210","journal-title":"J Pathol"},{"issue":"7","key":"1660_CR34","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","volume":"18","author":"TA Wynn","year":"2012","unstructured":"Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18(7):1028\u201340","journal-title":"Nat Med"},{"key":"1660_CR35","doi-asserted-by":"crossref","first-page":"438675","DOI":"10.1155\/2014\/438675","volume":"2014","author":"L Madaro","year":"2014","unstructured":"Madaro L, Bouch\u00e9 M (2014) From innate to adaptive immune response in muscular dystrophies and skeletal muscle regeneration: the role of lymphocytes. Biomed Res Int 2014:438675","journal-title":"Biomed Res Int"},{"issue":"1","key":"1660_CR36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2044-5040-1-21","volume":"1","author":"CJ Mann","year":"2011","unstructured":"Mann CJ, Perdiguero E, Kharraz Y, Aguilar S, Pessina P, Serrano AL, Mu\u00f1oz-C\u00e1noves P (2011) Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle 1(1):21","journal-title":"Skelet Muscle"},{"key":"1660_CR37","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.matbio.2018.01.014","volume":"68\u201369","author":"LR Smith","year":"2018","unstructured":"Smith LR, Barton ER (2018) Regulation of fibrosis in muscular dystrophy. Matrix Biol 68\u201369:602\u2013615","journal-title":"Matrix Biol"},{"issue":"2","key":"1660_CR38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/path.2213","volume":"213","author":"A Farini","year":"2007","unstructured":"Farini A, Meregalli M, Belicchi M, Battistelli M, Parolini D, D\u2019Antona G, Gavina M, Ottoboni L, Constantin G, Bottinelli R, Torrente Y (2007) T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid\/mdx mouse. J Pathol 213(2):229\u2013238","journal-title":"J Pathol"},{"issue":"1","key":"1660_CR39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40478-022-01320-z","volume":"10","author":"N Becker","year":"2022","unstructured":"Becker N, Moore SA, Jones KA (2022) The inflammatory pathology of dysferlinopathy is distinct from calpainopathy, Becker muscular dystrophy, and inflammatory myopathies. Acta Neuropathol Commun 10(1):17","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"1660_CR40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s13317-014-0062-2","volume":"5","author":"G Vattemi","year":"2014","unstructured":"Vattemi G, Mirabella M, Guglielmi V, Lucchini M, Tomelleri G, Ghirardello A et al (2014) Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis. Auto Immun Highlights 5(3):77\u201385","journal-title":"Auto Immun Highlights"},{"issue":"1","key":"1660_CR41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2044-5040-3-13","volume":"3","author":"S Rayavarapu","year":"2013","unstructured":"Rayavarapu S, Coley W, Kinder TB, Nagaraju K (2013) Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skelet Muscle 3(1):13","journal-title":"Skelet Muscle"},{"key":"1660_CR42","doi-asserted-by":"crossref","first-page":"e17240","DOI":"10.15252\/emmm.202217240","volume":"31","author":"A Argyriou","year":"2023","unstructured":"Argyriou A, Horuluoglu B, Galindo-Feria AS, Diaz-Boada JS, Sijbranda M, Notarnicola A et al (2023) Single-cell profiling of muscle-infiltrating T cells in idiopathic inflammatory myopathies. EMBO Mol Med.\u00a031:e17240","journal-title":"EMBO Mol Med"},{"issue":"2","key":"1660_CR43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/eji.201343315","volume":"44","author":"D McIntyre","year":"2014","unstructured":"McIntyre D, Zuckerman NS, Field M, Mehr R, Stott DI (2014) The V(H) repertoire and clonal diversification of B cells in inflammatory myopathies. Eur J Immunol 44(2):585\u2013596","journal-title":"Eur J Immunol"},{"issue":"1","key":"1660_CR44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1212\/WNL.50.1.41","volume":"50","author":"S Spuler","year":"1998","unstructured":"Spuler S, Engel AG (1998) Unexpected sarcolemmal complement membrane attack complex deposits on nonnecrotic muscle fibers in muscular dystrophies. Neurology 50(1):41\u201346","journal-title":"Neurology"},{"issue":"1","key":"1660_CR45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nmd.2022.10.005","volume":"33","author":"M Monforte","year":"2023","unstructured":"Monforte M, Attarian S, Vissing J, Diaz-Manera J, Tasca G (2023) \u201c265th ENMC workshop participants. 265th ENMC International Workshop: muscle imaging in facioscapulohumeral muscular dystrophy (FSHD): relevance for clinical trials\u201d. 22\u201324 April 2022, Hoofddorp, The Netherlands. Neuromuscul Disord 33(1):65\u201375","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"1660_CR46","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1111\/bcp.14884","volume":"87","author":"ML Mellion","year":"2021","unstructured":"Mellion ML, Ronco L, Berends CL, Pagan L, Brooks S, van Esdonk MJ et al (2021) Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: safety, tolerability, pharmacokinetics, and target engagement. Br J Clin Pharmacol 87(12):4658\u20134669","journal-title":"Br J Clin Pharmacol"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01660-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-023-01660-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01660-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T10:53:50Z","timestamp":1700477630000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-023-01660-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1660"],"URL":"https:\/\/doi.org\/10.1186\/s40478-023-01660-4","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"25 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All protocols were conducted according to the European Good Clinical Practice guidelines after the approval by the Ethical Committee of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS\u00a0(protocol ID 1524), and upon obtaining the written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}